First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Share :
Published: 19 Sep 2021
Views: 878
Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas

Prof Gabriel Hortobagyi talks to ecancer for the ESMO 2021 meeting about the overall survival results from the phase III MONALEESA study.

This study looked at the use of endocrine therapy with ribociclib in postmenopausal patients with HR positive and HER2 negative advanced breast cancer.

Prof Hortobagyi also reports that the advantage of the treatment seems to improve with time with the survival curves continuing to separate the longer the treatments go on.

Read more about this study here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.